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Background/Purpose: Oxidative stress is thought to be involved in the development of vascular
dysfunction. Arterial stiffness is one of the most signiﬁcant manifestations of aging and vascular disease.
We investigated whether increased malondialdehyde-modiﬁed low-density lipoprotein (MDA-LDL),
which is responsible for oxidative stress, was associated with increased arterial stiffness, independent of
confounders of cardiovascular disease.
Methods: The participants comprised 10 men aged 70 ± 7 years (range, 61e82 years) and 86 women
aged 67 ± 7 years (range, 53e81 years). Peripheral arterial stiffness was evaluated by the mean of the
right and left brachial to ankle pulse wave velocity (baPWV).
Results and conclusion: Both right and left baPWV values of Tertile-2 (61e81 U/L) and Tertile-3 (82
e218 U/L) categorized by tertiles of the MDA-LDL level were signiﬁcantly higher than those of Tertile-1
(34e60 U/L; p ¼ 0.022 and p ¼ 0.018, respectively). The multivariate-adjusted baPWV increased
signiﬁcantly from the lowest to the highest MDA-LDL group. Both baPWV values of Tertile-2 (61e81 U/L)
and Tertile-3 (82e218 U/L) were signiﬁcantly higher than those of Tertile-1 (34e60 U/L) (p ¼ 0.044 and
p ¼ 0.044, respectively). To further investigate whether MDA-LDL can explain baPWV levels independent
of other known confounding factors, multiple linear regression analyses for baPWV were conducted,
which showed that MDA-LDL levels (b ¼ 0.164, p ¼ 0.037) were independently and signiﬁcantly asso-
ciated with baPWV as well as gender, age, and presence of raised blood pressure. In addition, we found
that a slightly highenormal MDA-LDL level within a normal range is signiﬁcantly associated with a
higher baPWV. MDA-LDL levels are associated with an increased risk of arterial stiffness in community-
dwelling persons.
Copyright © 2016, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
In humans, oxidative stress is thought to be involved in the
development of vascular dysfunction1 and has been implicated in
the pathogenesis of aging, atherosclerosis,2 heart failure,3
myocardial infarction,4 diabetes,5 hypertension,6 and hypercho-
lesterolemia.7 Thus, increased oxidative modiﬁcation of low-
density lipoprotein (ox-LDL) as one indication of oxidative stressMedicine, Ehime University
ura-cho, Seiyo-City, Ehime
oto).
inical Gerontology & Geriatrics. Pub
d/4.0/).is also signiﬁcantly associated with lipid levels as well as blood
pressure and fasting plasma glucose (FPG), and is also awell-known
risk marker in the initiation and progression of cardiovascular
disease (CVD).8
Arterial stiffness, one of the most signiﬁcant manifestations of
aging, vascular disease, and hypertension, is altered primarily in
association with increased collagen content, alterations of extra-
cellular matrix protein (arteriosclerosis), and smooth muscle
cell.9,10 Arterial stiffness can be relatively simple and noninvasively
assessed by measuring pulse wave velocity (PWV),10 and the
assessment by brachialeankle PWV (baPWV) has recently been
proposed in Japan.11,12 Many studies have demonstrated that
increased baPWV is useful for discriminating middle-aged patients
with CVD12,13 and mortality.14 Thus, increased baPWV may be onelished by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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and CVD. The exact mechanisms underlying arterial stiffness,
however, remain unknown.
We investigated whether increased ox-LDL was associated with
increased arterial stiffness by measuring baPWV, and whether this
association is independent of gender, body mass index, and other
confounders of CVD. For this, we used cross-sectional data from
middle-aged and elderly community-dwelling persons.
2. Methods
2.1. Participants
The present study was designed as part of the Nomura study.15
The study population was selected through a community-based
annual check-up process from the Nomura Health and Welfare
Center in a rural town located in Ehime prefecture, Japan. Partici-
pants were enrolled in the study by public health nurses at the
health and welfare center. Physical activity level, information on
medical history, present conditions, and medications of the can-
didates were obtained through interviews. Those with CVDs or any
other major illnesses that could affect the laboratory test results
were excluded. All individuals aged 53e82 years with a clinically
documented diagnosis of hypertension, dyslipidemia, Type 2 dia-
betes, obesity, or any combination thereof were identiﬁed from the
case records. The study complies with the Declaration of Helsinki
and was approved by the Ethics Committee of Ehime University
School of Medicine, Ehime, Japan (UMIN000010611), with written
informed consent obtained from each participant.
2.2. Evaluation of risk factors
Information on demographic characteristics and risk factors was
collected using the clinical ﬁles at baseline. Body mass index was
calculated by dividing weight (in kilograms) by the square of the
height (in meters). We measured blood pressure with an
appropriate-sized cuff on the right upper arm of the participants in
a sedentary position using an automatic oscillometric blood pres-
sure recorder while they were seated after having rested for at least
5 minutes. The mean of two consecutive measurements was used
for the analysis. Triglycerides (TG), low-density lipoprotein
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C),
and FPG were measured during an overnight fast of > 11 hours.
Serum malondialdehyde-modiﬁed low-density lipoprotein (MDA-
LDL), which produces ox-LDL, was measured using an enzyme-
linked immunosorbent assay. Estimated glomerular ﬁltration rate
(eGFR) was calculated using the chronic kidney disease epidemi-
ology collaboration (CKD-EPI) equations modiﬁed by a Japanese
coefﬁcient (eGFRCKDEPI): maledCr 0.9 mg/dL, 141  (Cr/
0.9)0.411  0.993age  0.813, and Cr >0.9 mg/dL, 141  (Cr/
0.9)1.209  0.993age  0.813; female, Cr 0.7 mg/dL, 144  (Cr/
0.7)0.329  0.993age  0.813, and Cr >0.7 mg/dL, 144  (Cr/
0.7)1.209  0.993age  0.813.16 Histories of the use of antihyper-
tensive, antidyslipidemic, and antidiabetic medications were also
evaluated. Raised blood pressure was deﬁned as systolic blood
pressure 130 mmHg and/or diastolic blood pressure 85 mmHg,
and/or the current treatment for hypertension; elevated FPG was
deﬁned as an FPG level of  100 mg/dL or the current treatment for
diabetes mellitus.
2.3. Measurement of baPWV
PWV was measured using an automatic waveform analyzer
(PWV/ABI; Colin, Co., Ltd, Komaki, Japan). All individuals were
examined after resting in the supine position for at least 5 minutes,as described previously.17 This device records a phonocardiogram,
an electrocardiogram, a volume pulse form, and arterial blood
pressure at the left and right brachial arteries and ankles. Values of
baPWV were calculated using time-phase analysis between the
right brachial artery pressure and the volume waveforms at both
ankles. The distance between the right brachium and the ankle was
estimated based on the participant's height. We used the mean of
the right and left baPWVs as a marker of arterial stiffness.
2.4. Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics
version 20 (SPSS Japan, Inc., Tokyo, Japan). Data are presented as the
mean ± standard deviation unless otherwise speciﬁed, and for
parameters with a non-normal distribution (TG, MDA-LDL, and
baPWV), the data are shown as median (interquartile range) values.
In all analyses, parameters with a non-normal distribution were
used after log transformation. In these analyses, the participants
were divided into three categories based on the tertiles of theMDA-
LDL level (Tertile-1, 34e60 U/L; Tertile-2, 61e81 U/L; and Tertile-3,
82e218 U/L), and differences among the groups were analyzed by
Student t test for continuous variables or c2 test for categorical
variables. Pearson's partial correlations, after adjusting for gender
and age, were calculated in order to characterize the associations
between various characteristics and baPWV because the levels
increasedwith gender and age.17 Multiple linear regression analysis
was used to evaluate the contribution of each confounding factor to
baPWV. Analysis of covariance (ANCOVA) was performed using a
general linear model approach to determine the association be-
tween the confounding factors and baPWV in these analyses;
baPWV was the dependent variable, the three categories of MDA-
LDL levels were the ﬁxed factors, and signiﬁcantly confounding
factors were added as covariates. A p value < 0.05 was considered
signiﬁcant.
3. Results
3.1. Characteristics of various confounding factors of participants
categorized by tertiles of MDA-LDL level
Table 1 shows the characteristics of the participants categorized
by tertiles of the MDA-LDL level. The participants comprised 10
men aged 70 ± 7 years (range, 61e82 years) and 86 women aged
67 ± 7 years (range, 53e81 years). Systolic blood pressure, diastolic
blood pressure, TG, and LDL-C were signiﬁcantly higher in the
higher MDA-LDL group, but high-density lipoprotein cholesterol
was signiﬁcantly lower.
3.2. Gender- and age-adjusted PWV of participants categorized by
tertiles of MDA-LDL level
As shown in Table 2, both right and left baPWV values of Tertile-
2 (61e81 U/L) and Tertile-3 (82e218 U/L) were signiﬁcantly higher
than those of Tertile-1 (34e60 U/L).
3.3. Multivariate-adjusted baPWV of participants categorized by
MDA-LDL level
Figure 1 shows the multivariate-adjusted baPWV of participants
categorized by tertiles of the MDA-LDL level. BaPWV was adjusted
for gender, age, and presence of raised blood pressure. The
multivariate-adjusted baPWV increased signiﬁcantly from the
lowest to the highest MDA-LDL group categorized by tertiles of the
MDA-LDL level. Both baPWV values of Tertile-2 (61e81 U/L) and
Table 1
Characteristics of participants categorized by tertiles of the MDA-LDL level.a
Characteristics (N ¼ 96) MDA-LDL (U/L) p for trendb
Tertile-1 Tertile-2 Tertile-3
(34e60) (61e81) (82e218)
N ¼ 32 N ¼ 31 N ¼ 33
Gender (women) 28 (87.5) 30 (96.8) 28 (84.8) 0.265
Age (y) 68 ± 7 70 ± 6 66 ± 6 0.050
Body mass index (kg/m2) 24.2 ± 3.5 23.9 ± 2.6 25.2 ± 2.9 0.197
Body height (cm) 153.2 ± 6.9 150.3 ± 4.0 153.5 ± 9.7 0.277
Waist circumference (cm) 85.3 ± 8.8 85.7 ± 9.2 88.7 ± 8.8 0.248
Raised blood pressure (yes ¼ 1, no ¼ 0) 20 (62.5) 22 (71.0) 27 (81.8) 0.221
Systolic blood pressure (mmHg) 130 ± 19 140 ± 21 143 ± 24 0.036
Diastolic blood pressure (mmHg) 71 ± 11 76 ± 11 79 ± 13 0.039
Antihypertensive medication 9 (28.1) 10 (32.3) 14 (42.4) 0.458
Elevated fasting glucose (yes ¼ 1, no ¼ 0) 13 (40.6) 18 (58.1) 21 (63.6) 0.154
Fasting plasma glucose (mg/dL) 98 (91e110) 94 (101e115) 109 (98e124) 0.054
Antidiabetic medication 20 (62.5) 22 (71.0) 27 (81.8) 0.221
Triglycerides (mg/dL) 84 (55e107) 95 (69e126) 106 (71e134) 0.024
HDL cholesterol (mg/dL) 70 ± 16 71 ± 15 60 ± 14 0.007
LDL cholesterol (mg/dL) 110 ± 21 138 ± 29 146 ± 25 <0.001
MDA-LDL (U/L) 51 (47e57) 72 (66e76) 88 (84e103) <0.001
Antidyslipidemic medication 7 (21.9) 4 (12.9) 5 (15.2) 0.608
eGFR (mL/min/1.73 m2) 66.3 ± 11.1 69.1 ± 12.7 71.3 ± 12.2 0.257
Data are presented as n (%) or mean ± standard deviation. Data for triglycerides were skewed, presented as median (interquartile range), and log transformed for analysis.
ANOVA ¼ analysis of variance; eGFR ¼ estimated glomerular ﬁltration rate; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; MDA ¼ malondialdehyde.
a Bold ﬁgures indicate signiﬁcance (p < 0.05).
b One-way ANOVA test or c2 test.
Table 2
Gender- and age-adjusted pulse wave velocity of participants categorized by tertiles of the MDA low-density lipoprotein level.a,b
Characteristics (N ¼ 96) MDA low-density lipoprotein (U/L) p for trend*
Tertile-1 Tertile-2 Tertile-3
(34e60) (61e81) (82e218)
N ¼ 32 N ¼ 31 N ¼ 33
Right brachial to ankle (cm/s) 1506 (1429e1589) 1641 (1552e1734)* 1660 (1574e1750)* 0.022
Left brachial to ankle (cm/s) 1524 (1449e1603) 1652 (1570e1742)* 1679 (1592e1766)* 0.018
Mean brachial to ankle (cm/s) 1517 (1442e1596) 1648 (1563e1738)* 1667 (1585e1754)* 0.018
* p < 0.05 versus Tertile-1.
MDA ¼ malondialdehyde.
a Data presented are mean values (95% conﬁdence interval). Mean pulse wave velocity was obtained by averaging the right and left brachial to ankle pulse wave velocities.
Data for pulse wave velocity were skewed and log transformed for analysis.
b Bold ﬁgures indicate signiﬁcance (p < 0.05).
p = 0.044
p = 0.044 
34–60 U/L 61–81 U/L 82–218 U/L 
N = 32 N = 31 N = 33 
Tertiles of MDA low-density lipoprotein
1538 (1469–1611) 
1648 (1570–1726) 1644 (1570–1726) 
Figure 1. Multivariate-adjusted mean pulse wave velocity of participants categorized
by tertiles of the MDA-LDL level. Data presented are mean values (95% conﬁdence
interval). Multivariate adjustments were made for all signiﬁcantly confounding factors
in Table 3 (e.g., gender, age, and raised blood pressure). Data for pulse wave velocity
were skewed and log transformed for analysis. LDL ¼ low-density lipoprotein;
MDA ¼ malondialdehyde.
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Tertile-1 (34e60 U/L).
3.4. Relationship between various risk factors including MDA-LDL
and baPWV
To further investigate whether MDA-LDL levels can explain
baPWV levels independent of other known confounding factors,
multiple linear regression analyses for baPWV were performed
with the two models listed in Table 3. MDA-LDL levels were shown
to be independently and signiﬁcantly associated with baPWV as
well as gender, age, and presence of raised blood pressure.
4. Discussion
To determine the contribution of increased oxidative stress to
advanced arterial stiffness in the general population, we studied
the relationship between CVD risk factors including MDA-LDL,
which causes oxidative stress and arterial stiffness, in middle-
aged and elderly persons. This study showed that increased MDA-
LDL was independently associated with arterial stiffness, as
Table 3
Relationship between various confounding factors including MDA-LDL and pulse wave velocity.a
Characteristics (N ¼ 96) Gender- and age-adjusted
Pearson's correlation coefﬁcient
Forced entry method multiple
linear regression analysis
Stepwise method multiple
linear regression analysis
r p b p b p
Gender d d ¡0.169 0.079 ¡0.166 0.036
Age d d 0.497 <0.001 0.488 <0.001
Body mass index 0.066 0.530 0.126 0.405 d d
Waist circumference 0.014 0.896 0.098 0.505 d d
Raised blood pressure 0.451 <0.001 0.378 <0.001 0.364 <0.001
Elevated fasting glucose 0.036 0.731 0.032 0.700 d d
Triglycerides 0.128 0.220 0.022 0.827 d d
HDL cholesterol 0.057 0.586 0.055 0.620 d d
LDL cholesterol 0.127 0.222 0.038 0.713 d d
MDA-LDL 0.233 0.024 0.220 0.042 0.164 0.037
Antidyslipidemic medication 0.044 0.676 0.062 0.457 d d
eGFR 0.005 0.964 0.052 0.544 d d
R2 0.014 0.897 0.506 <0.001 0.468 <0.001
Data for pulse wave velocity, triglycerides and MDA-LDL were skewed and log transformed for analysis.
b¼ standard coefﬁcient; eGFR¼ estimated glomerular ﬁltration rate; HDL¼ high-density lipoprotein; LDL¼ low-density lipoprotein; MDA¼malondialdehyde; r¼ Pearson's
correlation coefﬁcient.
a Bold ﬁgures indicate signiﬁcance (p < 0.05).
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highenormal MDA-LDL level within a normal range (61e105 U/L)18
is signiﬁcantly associated with a higher baPWV.
Studies that demonstrate a relationship between MDA-LDL
within a normal range and PWV are very few. Brinkley et al19
showed that increased plasma ox-LDL levels (p ¼ 0.008) were
associated with higher aortic PWV after adjustment for traditional
CVD risk factors, among 2295 elderly persons (mean age, 74 years;
52% female; 40% black). Mean aortic PWV increased signiﬁcantly
across tertiles (Tertile-1, 1.22e9.1 mg/L; Tertile-2, 9.1e13.4 mg/L;
and Tertile-3, 13.4e73.1 mg/L) of ox-LDL (869 ± 376 cm/s,
901± 394 cm/s, and 938± 415 cm/s, respectively; p¼ 0.002). Zagura
et al20 showed that serum ox-LDL levels are independently associ-
ated with aortic PWV among 42 menwith symptomatic peripheral
arterial disease (aged 66 ± 7 years) and 46 healthy men (aged
66± 8 years). Froma 3-year longitudinal, observational study of 288
middle-aged adults notmeeting the criteria formetabolic syndrome
at the initial screening, age-related increase inbaPWVwasgreater in
the presence of metabolic syndrome with higher levels of inﬂam-
matory and oxidative stress markers.21 In our study, multivariate-
adjusted baPWV increased signiﬁcantly from the lowest to the
highest MDA-LDL group categorized by tertiles of the MDA-LDL
level; a slightly highenormal MDA-LDL level within a normal
range22 was also signiﬁcantly associated with a higher baPWV.
The mechanisms that lead to higher baPWV in individuals with
increased MDA-LDL are not completely understood. We assumed
that there are several possible mechanisms linking MDA-LDL and
arterial stiffness. MDA-LDL is thought to be involved in many pro-
cesses of atherosclerosis; it is a promising candidate as a risk factor
for atherosclerosis in addition to the established risk factors such as
aging, gender, hypertension, diabetes, and LDL-C. MDA-LDL has
been reported to exert direct cytotoxicity on endothelial cells,
promote synthesis and secretion of adhesion molecules, increase
platelet aggregation and monocyte adhesion, and enhance foam
cell formation in atherosclerotic lesions, all of which lead to the
remodeling of vessel walls.23,24 Formation of ox-LDL in the sub-
endothelial space of arterial walls is an important initiation step for
atherosclerosis because it contributes to foam cell generation, in-
ﬂammatory processes, and endothelial dysfunction.25 MDA-LDL
also correlated with established risk factors such as systolic blood
pressure, diastolic blood pressure, TG, high-density lipoprotein
cholesterol, and LDL-C, which were independently associated with
arterial stiffness.26e28 In our study, however, MDA-LDL levels were
signiﬁcantly and independently associated with baPWV.Several limitations of this study must be considered. First, based
on its cross-sectional design, the present ﬁndings are inherently
limited in the ability to eliminate causal relationships between risk
factors and baPWV. Second, since the majority of the study popu-
lation had several risk factors, including insulin resistance, hyper-
tension, and an advanced age, we could therefore not eliminate the
possible effects of underlying diseases and medications used for
hypertension and dyslipidemia on the present ﬁndings. Third,
MDA-LDL is based on a single assessment, which may introduce
misclassiﬁcation bias. Therefore, the demographics and referral
source may limit generalizability of the study ﬁndings.
In conclusion, the present study showed that a slightly high-
enormal MDA-LDL level was associated with an increased risk of
baPWV in middle-aged and elderly persons. The underlying
mechanism behind this relationship is unclear, but it seems to be
independent of traditional cardiovascular risk factors such as age,
body mass index, hypertension, dyslipidemia, and renal function.
Further prospective population-based studies are needed to
investigate the mechanisms underlying this association.
Conﬂicts of interest
The authors declare that they have no competing interests.
Acknowledgments
This work was supported in part by a grant-in-aid for Scientiﬁc
Research fromthe Foundation forDevelopmentofCommunity (2015).
References
1. Nedeljkovic ZS, Gokce N, Loscalzo J. Mechanisms of oxidative stress and
vascular dysfunction. Postgrad Med J 2003;79:195e9.
2. Bonomini F, Tengattini S, Fabiano A, Bianchi R, Rezzani R. Atherosclerosis and
oxidative stress. Histol Histopathol 2008;23:381e90.
3. Singh N, Dhalla AK, Seneviratne C, Singal PK. Oxidative stress and heart failure.
Mol Cell Biochem 1995;147:77e81.
4. Ramond A, Godin-Ribuot D, Ribuot C, Totoson P, Koritchneva I, Cachot S, et al.
Oxidative stress mediates cardiac infarction aggravation induced by intermit-
tent hypoxia. Fundam Clin Pharmacol 2011;27:252e61.
5. Ramakrishna V, Jailkhani R. Oxidative stress in non-insulin-dependent diabetes
mellitus (NIDDM) patients. Acta Diabetol 2008;45:41e6.
6. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res
2006;71:247e58.
7. Yang RL, Shi YH, Hao G, Li W, Le GW. Increasing oxidative stress with pro-
gressive hyperlipidemia in human: relation between malondialdehyde and
atherogenic index. J Clin Biochem Nutr 2008;43:154e8.
R. Kawamoto et al. / Journal of Clinical Gerontology & Geriatrics 7 (2016) 136e1401408. Stocker R, Keaney Jr JF. Role of oxidative modiﬁcations in atherosclerosis.
Physiol Rev 2004;84:1381e478.
9. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardio-
vascular disease enterprises: part I: aging arteries: a “set up” for vascular
disease. Circulation 2003;107:139e46.
10. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular
disease enterprises: part III: cellular and molecular clues to heart and arterial
aging. Circulation 2003;107:490e7.
11. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, et al. Validity,
reproducibility, and clinical signiﬁcance of noninvasive brachialeankle pulse
wave velocity measurement. Hypertens Res 2002;25:359e64.
12. Yamashina A, Tomiyama H, Arai T, Hirose K, Koji Y, Hirayama Y, et al. Bra-
chialeankle pulse wave velocity as a marker of atherosclerotic vascular dam-
age and cardiovascular risk. Hypertens Res 2003;26:615e22.
13. Xu Y, Wu Y, Li J, Ma W, Guo X, Luo Y, et al. The predictive value of bra-
chialeankle pulse wave velocity in coronary atherosclerosis and peripheral
artery diseases in urban Chinese patients. Hypertens Res 2008;31:1079e85.
14. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR,
et al. Relationship of high and low ankle brachial index to all-cause and car-
diovascular disease mortality: the Strong Heart Study. Circulation 2004;109:
733e9.
15. Kawamoto R, Kohara K, Katoh T, Kusunoki T, Ohtsuka N, Abe M, et al. Effect of
weight loss on central systolic blood pressure in elderly community-dwelling
persons. Hypertens Res 2014;37:933e8.
16. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of
chronic kidney disease in the Japanese general population. Clin Exp Nephrol
2009;13:621e30.
17. Kohara K, Tabara Y, Tachibana R, Nakura J, Miki T. Microalbuminuria and
arterial stiffness in a general population: the Shimanami Health Promoting
Program (J-SHIPP) study. Hypertens Res 2004;27:471e7.
18. Matsuo Y, Kubo T, Okumoto Y, Ishibashi K, Komukai K, Tanimoto T, et al.
Circulating malondialdehyde-modiﬁed low-density lipoprotein levels areassociated with the presence of thin-cap ﬁbroatheromas determined by optical
coherence tomography in coronary artery disease. Eur Heart J Cardiovasc Im-
aging 2013;14:43e50.
19. Brinkley TE, Nicklas BJ, Kanaya AM, Satterﬁeld S, Lakatta EG, Simonsick EM,
et al. Plasma oxidized low-density lipoprotein levels and arterial stiffness in
older adults: the health, aging, and body composition study. Hypertension
2009;53:846e52.
20. Zagura M, Kals J, Kilk K, Serg M, Kampus P, Eha J, et al. Metabolomic signature
of arterial stiffness in male patients with peripheral arterial disease. Hypertens
Res 2015;38:840e6.
21. Kim OY, Paik JK, Lee JY, Lee SH, Lee JH. Follow-ups of metabolic, inﬂammatory
and oxidative stress markers, and brachialeankle pulse wave velocity in
middle-aged subjects without metabolic syndrome. Clin Exp Hypertens
2013;35:382e8.
22. Kotani K, Tashiro J. MDA-LDL. Med Technol 2009;37:121e6.
23. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherosclerosis.
Free Radic Biol Med 1996;20:707e27.
24. Steinberg D. Low density lipoprotein oxidation and its pathobiological signif-
icance. J Biol Chem 1997;272:20963e6.
25. Verhoye E, Langlois MR, Asklepios Investigators. Circulating oxidized low-
density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk?
Clin Chem Lab Med 2009;47:128e37.
26. Kawamoto R, Tabara Y, Kusunoki T, Abe M, Kohara K, Miki T. A slightly high-
normal glucose level is associated with increased arterial stiffness in Japa-
nese community-dwelling persons with pre-diabetes. Vasc Med 2013;18:
251e6.
27. Jung CH, Yu JH, Bae SJ, Koh EH, Kim MS, Park JY, et al. Serum gamma-
glutamyltransferase is associated with arterial stiffness in healthy in-
dividuals. Clin Endocrinol (Oxf) 2011;75:328e34.
28. Wen JH, Zhong YY, Wen ZG, Kuang CQ, Liao JR, Chen LH, et al. Triglyceride to
HDL-C ratio and increased arterial stiffness in apparently healthy individuals.
Int J Clin Exp Med 2015;8:4342e8.
